Precision Medicine

A new blood test and a powerful partnership between a diagnostics firm and a patient foundation aim to end years of misdiagnosis for a rare lung disease.

A German biotech just completed a key trial for a cell therapy that could teach the body to accept a new kidney, freeing patients from a lifetime of harsh drugs.

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.

A new partnership brings advanced, FDA-cleared HPV testing to the home. The true innovation, however, is the system built to overcome the last-mile problem.

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

The animal health leader faces scrutiny in its Q2 earnings call after a rocky first quarter. All eyes are on its strategy to balance market pressures with future-focused bets.

A new deal in Israel signals a shift from noisy, ineffective warnings to precise, life-saving insights. Is this the future of personalized medication safety?

By combining vast datasets with patient-driven advocacy, a new alliance offers hope for angiosarcoma patients and a new model for rare disease research.

As Abbott prepares its July 16th earnings report, all eyes are on more than just the balance sheet. It's a test of its post-acquisition strategy.

A Virginia nonprofit's AI platform, backed by Pentagon funding, has decoded the deadly impact of radiation on the gut, paving the way for new countermeasures.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

Carolyn Starrett's appointment to the NeoGenomics board signals a major push to integrate AI and real-world data into the core of cancer diagnostics.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Johnson & Johnson's new platform combines RF and PF ablation, moving beyond the hype of single-modality tech to offer physicians unprecedented versatility.

IBA's deal to build Brazil's first proton therapy center is more than a medical breakthrough; it's a high-stakes play for market dominance in Latin America.

A new ARPA-H grant aims to replace 50-year-old tech with a rapid blood test for fetal hypoxia, a move that could slash C-sections and save lives.

The FDA has approved TRYNGOLZA, the first drug to reduce triglycerides and acute pancreatitis risk, marking a new era for millions and a pivotal moment for Ionis.

Researchers have developed a nanoparticle that mimics diseased cells, allowing for rapid screening of cancer targets. It's a key step toward truly personal vaccines.

Promising Phase 2 data for AP-101 shows it slows ALS progression by targeting a key toxic protein, offering new hope beyond purely genetic approaches.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.